CClinicalTrials.gg
Not yet recruitingNCT07781774Updated Aug 24, 2026

Improving Colorectal Cancer Screening Uptake Through Education and Stool-Based Testing Outreach

An interventional study of Colorectal Cancer Education Materials and Cologuard test kit in Colorectal Cancer (CRC) Screening, CRC Screening and Rectal Cancer, sponsored by Washington University School of Medicine. Not yet recruiting at 1 site in United States. Open to participants aged 45 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Study summary

This is a mixed-methods implementation pilot combining an educational intervention with a mailed stool-based testing outreach feasibility study within a resident primary care clinic. Participants will be assigned by clinic team to education, mailed FIT, mailed Cologuard, or usual care comparison groups.

02

Conditions studied

  • Colorectal Cancer (CRC) Screening
  • CRC Screening
  • Rectal Cancer
  • Colon Cancer
  • Colorectal Cancer

Keywords

  • Colorectal cancer
  • Screening
  • Primary care
  • Teaching clinics
03

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Phase 1 Education Arm Inclusion Criteria:

  • Previously enrolled in prior study IRB #202202059 who agreed to participate in future research

Phase 1 Education Arm Exclusion Criteria:

  • Not enrolled in prior study IRB #202202059

Phase 2 (All Other Arms) Inclusion Criteria:

  • Primary Care Medicine Clinic patient (PRMC)
  • Eligible for CRC screening
  • Between age 45-75 years old
  • Have eligible health insurance

Phase 2 (All Other Arms) Exclusion Criteria:

  • Prior history of colorectal cancer
  • Diagnosis of inflammatory bowel disease
04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Education

    Participants will complete the Assessment of Colon Cancer Literacy (ACCL) as a pre-test prior to receiving education materials. After the pre-test, participants will be provided with ACCL education materials. Three months after being provided education materials, participants will repeat ACCL testing.

    Behavioral: Colorectal Cancer Education Materials

  • Experimental
    Mailed FIT

    Participants will receive a mailed package including 1 FIT test, step-by-step written and pictorial instructions, a prepaid, trackable return envelope, a brief explanation of how the testing works and how results will be communicated, and education materials about CRC. Participants who return kits will complete the Client Satisfaction Questionnaire (CSQ-3) by phone or via MyChart. Participants will be contacted three times by phone as reminders to complete the kit. After three reminders, the team will stop attempting to contact the patient.

    Diagnostic Test: Fecal immunochemical test kit

  • Experimental
    Mailed Cologuard

    Participants will receive a mailed package including 1 Cologuard test, step-by-step written and pictorial instructions, a prepaid, trackable return envelope, a brief explanation of how the testing works and how results will be communicated, and education materials about CRC. Participants will have 3 months to return the kit. Participants who return kits will complete the Client Satisfaction Questionnaire (CSQ-3) by phone or via MyChart. Participants will be contacted three times by phone as reminders to complete the kit. After three reminders, the team will stop attempting to contact the patient.

    Diagnostic Test: Cologuard test kit

  • Active comparator
    Usual Care

    Participants will receive usual care from provider after enrollment with no intervention. Usual care includes providers offering standard screening options including FIT, Cologuard, and colonoscopy at the initial visit with no default option or structured follow-up.

    Behavioral: Usual Care

Interventions

  • BehavioralColorectal Cancer Education Materials

    Education materials are compiled from the American College of Gastroenterology (ACG) and the City of Hope. The education materials are at a 6th grade reading level. Materials detail digestive system and polyp background, colorectal cancer (CRC) risk factors, warning signs, screening options, recommended initial screening age, and stool-based screening and colonoscopy processes.

  • Diagnostic testCologuard test kit

    The Cologuard test will be mailed to the participants. Participants will complete the test via the step-by-step written and pictorial instructions provided and mail the complete test with the pre-paid return label provided.

  • Diagnostic testFecal immunochemical test kit

    The Fecal immunochemical test (FIT) will be mailed to the participants. Participants will complete the test via the step-by-step written and pictorial instructions provided and mail the complete test with the pre-paid return label provided.

  • BehavioralUsual Care

    Usual care for patients eligible for colorectal cancer screening will be provided by the Barnes-Jewish Hospital Primary Care Medicine Clinic.

05

What researchers measure

Primary outcomes

  1. Change in CRC knowledge (Education Arm only)

    Change in CRC knowledge will be measured by changes in the score of the Assessment of Colon Cancer Literacy (ACCL) test. The ACCL consists of 10-items with True/False/Unsure. The ACCL score ranges from 0 to 10 with a score of 7-10 indicating adequate literacy and scores of 0-6 indicating limited literacy.

    Time frame: At enrollment and 3 months after educational intervention (total estimated time is 3 months)

  2. Feasibility as measured by the percentage of kits returned (Mailed FIT and Mailed Cologuard Arms only)

    Time frame: At 3 months after receiving kit (total estimated time 3 months)

  3. Acceptability of stool based testing (Mailed FIT and Mailed Cologuard Arms only)

    Acceptability will be assessed using the 3-item Customer Service Questionnaire (CSQ-3). The 3-items are rated on a 4-point Likert scale as follows: 1=Poor, 2=Fair, 3=Good, and 4=Excellent. Generally, the higher the score indicates greater customer satisfaction.

    Time frame: At completion of testing or at 3 months after receiving test kit (total estimated time 3 months)

  4. CRC screening completion rate (All arms)

    CRC screening completion rate will be assessed through electronic health record (EHR) verification of screening completion.

    Time frame: From time of receiving CRC kit to 6 months after receiving kit (total estimated time 6 months)

06

Study locations

1 site
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    • Cassandra Fritz, MD, MPHS · Contact · cfritz@wustl.edu · 314-454-8165
    • Darren Nix · Contact · nixd@wustl.edu · 314-362-3201
    • Kamilah Scales, MD · Sub investigator
07

References and documents

08

Registry details

Key details

Study ID
NCT07781774
Lead sponsor
Washington University School of Medicine
Responsible party
Sponsor
First posted
Aug 24, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Aug 24, 2026

Study contacts

Cassandra Fritz, MD, MPHS
Contact
cfritz@wustl.edu
314-454-8165
Darren Nix
Contact
nixd@wustl.edu
314-362-3201
Cassandra Fritz, MD, MPHS
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion